This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Goldman Sachs, Morgan: Premarket Trading

Stocks in this article: GSMSXINGJPMBARCENDPMBIC

(Premarket story updated with Goldman Sachs and Morgan Stanley news, as well as share price information.)
NEW YORK ( TheStreet) -- Yesterday Calyon Securities analyst Mike Mayo lowered his estimates for Goldman Sachs (GS) and Morgan Stanley (MS) on worries about the weakness in rates products. Mayo lowered his fourth-quarter earnings estimate for Morgan Stanley to 40 cents per share from 61 cents, while decreasing his expectation for Goldman to $3.75 per share from $4.20.

Morgan Stanley is down 0.07%, or 2 cents, to $27.26, while Goldman Sachs is dropping 0.08%, or 13 cents, to $167.50 in premarket trading.







Qiao Xing Universal Resources (XING) announced yesterday that it posted pictures of a newly acquired mine online and that it plans to launch a new Web site in early January.

"We are making continuous efforts to enhance our transparency and improve communications with investors to convey the exciting developments within our company," Qiao Xing chairman and CEO Ruilin Wu said. "As part of these efforts, we are also considering an on-site visit in the spring of 2011 in Chifeng, where most of our mining businesses are located."

Shares of the company are climbing 9.59%, or 26 cents, to $2.97 in premarket trading.






JPMorgan Chase (JPM) and Barclays (BARC) said they will not oppose MBIA's (MBI) plan to split its municipal bond insurance business from its structured finance operations. U.S. bond insurer MBIA is receiving opposition from over a dozen major banks including Citigroup (C) and Morgan Stanley.

MBIA shares are down 0.01%, or 1 cents, to $10.35 in premarket trading.






Endo Pharmaceuticals (ENDP) received regulatory approval from the Food and Drug Administration for its Fortesta gel product for the treatment of men with low testosterone. Endo expects to launch the product in the U.S. in early 2011.

Shares of the company are up 6.47%, or $2.28, to $37.50 in premarket trading.


1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,036.35 +62.04 0.37%
S&P 500 0.00 -2.75 -0.14%
NASDAQ 4,545.6470 -3.5790 -0.08%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs